247wallst.com · 10 jul

Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.

zacks.com · 9 jul

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

fool.com · 8 jul

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.

fool.com · 7 jul

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

fool.com · 7 jul

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

zacks.com · 6 jul

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

fool.com · 6 jul

3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

seekingalpha.com · 3 jul

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.